

ARIA Workgroup Member Affiliations and Disclosures

Disclosures have been made for the past 36 months using the ICMJE form collection

**** Indicates payment > \$5,000 per year**

Alireza Atri is employed by Banner Sun Health Research Institute, Banner Health. He serves on several Alzheimer's Association workgroups on a pro bono basis and has not received compensation or honoraria for his participation in any workgroup, including his involvement in this ARIA Workgroup. He has received meeting support from the Alzheimer's Association for unrelated meetings/conferences. He has served as a site Principal Investigator (PI) for biopharma-sponsored clinical trials at his institution, including those funded by Alzheon, Athira, and Biogen. Additionally, he has acted as a site PI for biopharma-AD consortium collaborative sponsored clinical trials at his institution, including those supported by Biohaven (with ADCS), Eisai (with ATRI/ACTC), Lilly (with ATRI/ACTC), and Vivoryon (with ADCS). He has served as a site PI for clinical trials or grants sponsored or co-sponsored by Research Consortia or Institutes, including ACTC, ADCS, AZ Alzheimer's Research Consortium and AZ DHS, ATRI, and GAP. He has served as a site PI for collaborative clinical trials sponsored or co-sponsored by universities, including the University of Southern California (USC), Indiana University, and Johns Hopkins University. He is a project Arm Leader for an international clinical trial at Washington University St. Louis. He has received grants from Gates Ventures, AZ DHS, and NIA/NIH. He has served as the PI for the Single Site Biomarker (SV2A-PET) study funded by FNIH. He holds royalties or licenses for a book on dementia published by Oxford University Press. He has received consulting fees from Lundbeck** (past/completed, payment received in the last 24 months), Novo Nordisk** (current, payment received in the last 24 months), Eisai** (current, payment received in the last 24 months), Prothena** (past/completed, payment expected to be received – no \$'s received thus far), Roche/Genetech** (past/completed, payment received for work completed over 6 years prior to 24 months ago \$'s received in one tranche), Merck (current), ONO** (past/completed, payment expected to be received – no \$'s received thus far), AriBio** (past/completed, payment received in the last 24 months), Vaxxinity** (past/completed, payment expected to be received – no \$'s received thus far), Life Molecular Imaging** (current, payment expected to be received – no \$'s received thus far) and Axome** (past/completed, payment received in the last 24 months). He has received payment or honoraria for lectures, presentations, or educational events from Eisai** (payment received in the last 24 months) and Lundbeck** (payment received in the last 24 months). He has received travel or meeting support specifically for consulting meetings, workgroup sessions, scientific/medical presentations, or educational programs from the Alzheimer's Association, Alzheimer's Disease International (ADI), and the American Academy of

Neurology (AAN). He has participated on a Data Safety Monitoring Board or Advisory Board for Roche/Genetech** (past/completed, payment expected to be received – no \$'s received thus far).

Tammie L. S. Benzinger is employed by Washington University. She has received grants or contracts from Siemens paid to her institution; consulting fees from Biogen** (\$5,000-10,000), Eli Lilly, Eisai** (\$5,000-10,000), Bristol Myers Squibb, J&J, and Merck; payment for CME activity from Medscape, PeerView, and Neurology Today; and travel reimbursement from Cedars Sinai Medical Center, Hong Kong Neurological Association and the Alzheimer's Association. She reports the following patents planned, issued or pending: US patent 16/097, 457 (DIFFUSION BASIS SPECTRUM IMAGING (DBSI), A NOVEL DIFFUSION MRI METHOD USED TO QUANTIFY NEUROINFLAMMATION AND PREDICT ALZHEIMER'S DISEASE (AD) PROGRESSION), and US Patent 12,016,701 (Quantitative Differentiation of Tumor Heterogeneity Using Diffusion MR Imaging Data). She has participated in a Data Safety Monitoring Board or Advisory Board of Siemens and served as an external advisor for NIH-funded studies (no payments). She has served as the co-chair of ASNR Alzheimer's, ARIA and Dementia Study Group, and RSNA Quantitative Imaging Committee (QuIC) (all unpaid). She has served as a committee member of the American College of Radiology/ALZ NET imaging, NIH CNN Study Section Chair, and had a leadership or fiduciary role in the ACR Commission on Neurology (all unpaid). She has received technology transfer and precursors for radiopharmaceuticals from Avid Radiopharmaceuticals/Eli Lilly, LMI, and Lantheus, as well as a scanner loan from Hyperfine to her institution. For additional references regarding her disclosures, see Sunshine ACT reporting here: <https://openpaymentsdata.cms.gov/physician/850680>.

Francesca Bosetti is an ex officio representative of the ARIA workgroup. She is employed by the National Institute of Health - National Institute of Neurological Disorders and Stroke (NIH-NINDS), and has no financial conflicts to disclose.

Maria C. Carrillo is a full-time employee of the Alzheimer's Association and has a daughter in the neuroscience program at USC. She has no financial conflicts to disclose.

Petrice M. Cogswell is employed by Mayo Clinic. She has received consulting fees from Eli Lilly & Co. and payment for medical education presentations from Eisai Inc.** and Kaplan. She has received travel payment from the American Academy of Neurology for scientific presentations. She has also served as co-chair of ASNR Alzheimer's, ARIA and Dementia study group (no compensation). In addition, she will be serving on the Data Safety Monitoring Board for study E2814-202, where no payments will be made to her or her institution.

Ellis van Etten is employed by Leiden University Medical Center. She has received the Early Career Grant from Alzheimer Nederland** and funding to cover travel expenses and accommodation to attend the international CAA conference in Munich and the LeDucq consortium, both in October 2024. In addition, she has participated as a member of the steering committee for a Phase II trial for CAA initiated by Alnylam Pharmaceuticals Inc. on a pro bono basis.

Steven M. Greenberg is employed by Harvard Medical School, Massachusetts General Hospital. He has received research grants from the National Institute of Health**, author royalties from UpToDate, and consulting fees from Eli Lilly Co (this relationship ended in 3/2022). In addition, he has participated in the Global Steering Committee of Alnylam, where payments were made to his institution, and participated in the Safety Monitoring Committee of Washington University**, Bayer, and Bristol Myers Squibb.

Joshua Grill is employed by the University of California, Irvine. He has received grant funding from the National Institute of Aging**, the Alzheimer's Association**, and the BrightFocus Foundation**. He has also received grants or contracts from Eli Lilly**, Genentech**, Biogen**, and Eisai**, all related to sponsored clinical trials. In addition, he has received consulting fees from Banner Alzheimer's Institute** and SiteRx, support for attending meetings and/or travel from the Alzheimer's Association, and equipment, materials, drugs, medical writing, gifts, or other services from Innovate.

Costantino Iadecola is employed by Weill Cornell Medicine. He has received the following grants from NIH, all paid to his institution: RF1-NS128947, High-speed imaging of cortical and white matter microvascular flow in AD/ADRD models, Multi-PI: C.B. Schaffer; C. Xu; C. Iadecola, period: 8/22-7/25; R01-NS095441, Dietary sodium, neurovascular dysfunction and cerebrovascular risk, period: 7/21-6/26; 1R01-NS126467, ApoE4, neurovascular injury and cognitive impairment, period: 4/22-3/27; R01-NS/HL37853, Alzheimer Pathology and Neurovascular Dysfunction, period: 1/23-12/27. In addition, he has received payment for participation on a Data Safety Monitoring Board or Advisory Board of Broadview Ventures.

Takeshi Iwatsubo is employed by the University of Tokyo. He received honoraria for lectures from Eli Lilly and Eisai.

Clifford R. Jack Jr. is employed by Mayo Clinic. He has received grant funding from the National Institute of Health. He has also served on a DSMB for Roche on a pro bono basis, for which no payments were made to him or his institution (Mayo Clinic).

Cynthia A. Lemere is employed by Harvard Medical School, Brigham and Women's Hospital. She has received grants from the National Institutes of Health (NIA, NINDS),

NASA, Cure Alzheimer's Fund and Apellis Pharmaceuticals (sponsored research), all paid to her institution. She has received consulting fees from Acumen**, ADvantage Therapeutics**, Alnylam Pharmaceuticals**, Apellis Pharmaceuticals**, Biogen**, Biohaven Pharmaceuticeuticals, Cambridge Healthcare Consulting Group, Cyclo Therapeutics**, Eli Lilly & Co, Luxembourg National Research Fund, MEDAcorp, Merck**, MINDImmune Therapeutics, Novo Nordisk**, Takeda and Switch Therapeutics. She has received Honoraria for invited seminars from AC Immune, Alnylam Pharmaceuticals, Boston University School of Medicine, Cyclo Therapeutics, Merck**, Michigan State University, Novo Nordisk, Sanofi**, and UCI. She has received Honoraria for grant proposal reviews from NIH, BrightFocus Foundation, Brookhaven National Laboratory, and Cure Alzheimer's Fund. She received an Honorarium from the Kenes Group for serving as an AD/PD Meeting Executive Organizer**. She has received travel support to attend meetings from the Alzheimer's Association, Biohaven Pharmaceuticals, the BrightFocus Foundation, the Fraunhofer Institute (Haale, Germany), Indiana University, Kenes Group (AD/PD Meeting**), Luxembourg National Research Fund**, Merck, Michigan State University, Novo Nordisk, Sanofi**, and UCI. She has served on the Scientific Advisory Board of the Alzheimer's Association US POINTER, and is a Member/Advisor of the DIAN-TU Therapeutic Evaluation Committee, DSMB of LuMIND, External Advisory Board of NIH MARMO-AD, and External Advisory Board (Chair) of NIH MODEL-AD. She has served as a Member, Chair, Past Chair, and Alumni of the Alzheimer's Association Medical and Scientific Advisory Group (MSAG), and is a Co-organizer of Alzheimer's FastTrack Workshop for BrightFocus Foundation, and a Member/Advisor for Cure Alzheimer's Fund Research Leadership Council. She has <1% stock options at Acumen and MINDImmune and has received anti-amyloid antibodies for nonclinical research from Vivoryon Therapeutics. Her husband owns Gerald Cox Rare Care Consulting, LLC.

Simin Mahinrad is a full-time employee of the Alzheimer's Association. She has no financial conflicts to disclose.

James A.R. Nicoll is Emeritus Professor at the University of Southampton, U.K. He received support (travel, accommodation and subsistence) from the American Heart Association to present at the International Stroke Conference in Phoenix, Arizona, 2024.

Laurie M. Ryan is an ex officio representative of the ARIA workgroup. She is employed by the National Institute of Health - National Institute of Aging (NIH-NIA), and has no financial conflicts to disclose.

Stephen Salloway is employed by Brown University. Butler Hospital receives research support for conducting clinical trials through grants or contracts from Biogen, Eisai, Genentech, Roche, CognitionRx, Lilly, and Janssen. He has received consulting fees from Abbvie, Acumen, Alector, Biogen, Biohaven, Cognition, Eisai, Fujirebio, Genentech,

Kisbee, Laqbcorp, Merck, Lilly**, Neurophet**, NovoNordisk**, Prothena, Quest, and Roche; and travel expenses for attending meeting from Abbvie, Acumen, Lilly, and Neurophet.

Reisa Sperling is employed by Harvard Medical School, Brigham and Women's Hospital. She has received grant funding from the Alzheimer's Association, NIH and the GHR foundation, all paid to her institution. She has also received research funding to clinical trial sites from Eli Lilly (institutional funding) and Eisai. She has received consulting fees from Abbvie, AC Immune, Acumen, Alector, Apellis, Biohaven, Bristol Myers Squibb, Genentech, Ionis, Janssen, Nervgen, Oligomerix, Prothena, Roche, Vigil Neuroscience, and Vaxxinity. Her spouse has received consulting fees from Novartis, Merck, Janssen and Sanofi. Dr. Sperling has received travel reimbursement for attending meetings from the Alzheimer's Association and hotel and airfare reimbursement for attending meetings from Clinical Trials in Alzheimer's Disease.

Last updated May 6, 2025